First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes by Jean Van Rampelbergh, Peter Achenbach, Richard David Leslie, Mohammad Alhadj Ali, Colin Dayan, Bart Keymeulen, Katharine R. Owen, Martin Kindermans, Frédéric Parmentier, Vincent Carlier, Roxana R. Ahangarani, Evelien Gebruers, Nicolas Bovy, Luc Vanderelst, Marcelle Van Mechelen, Pierre Vandepapelière, Christian Boitard

Get full text